Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
experimental group:Liushen pill and basic treatment
control group:basic treatment
Sponsors
The Fifth People's Hospital of Suzhou
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; no gender limit; 2. Mild and common patients diagnosed with the novel coronavirus infection (the diagnosis criteria shall be based on the criteria of the novel coronavirus Pneumonia Diagnosis and Treatment Protocol (Trial Edition 8) issued by the National Health Commission, and if updated, the criteria of the new version of the diagnosis and treatment protocol shall be applied); 3. Patients who have been tested positive for the novel coronavirus for the first time for >=14 days; 4. The patients voluntarily joined the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Respiratory infections caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, abnormal lung development and other basic diseases, with clear evidence of bacterial infection; 2. Patients with the following conditions: asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory diseases affecting the evaluation of the clinical trial. Chest CT confirmed the presence of serious pulmonary interstitial lesions, bronchiectasis and other underlying lung diseases; 3. Patients with severe pneumonia requiring mechanical ventilation; 4. Previous or current medical conditions that may affect the outcome of the trial or study, as determined by the investigator, include: malignant diseases, autoimmune diseases, liver and kidney diseases, hematologic diseases, neurological diseases, and endocrine diseases; Having a disease that seriously affects the immune system, such as human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy or organ transplantation; 5. Pregnant or lactating patients; 6. Patients who have participated in other clinical trials within the last 1 month; 7. Allergic constitution, such as allergic history of two or more drugs or food, or known allergy to the ingredients of this medicine; 8. The investigator determined that there were any factors that were not suitable for inclusion in the study or that affected the efficacy evaluation of the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to turn negative after the treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Virus turn negative time (from first positive test to virus turn negative);Improvement of clinical symptoms; | — |
Countries
China
Contacts
Public ContactTao Tao, Zhang Jianping
The Fifth People's Hospital of Suzhou
Outcome results
None listed